Featured Jobs
|
Retirement Plan Administration Consultant Blue Ridge Associates
|
|
Compass
|
|
BPAS
|
|
Cash Balance/ Defined Benefit Plan Administrator Steidle Pension Solutions, LLC
|
|
Mergers & Acquisition Specialist Compass
|
|
Relationship Manager for Defined Benefit/Cash Balance Plans Daybright Financial
|
|
MAP Retirement
|
|
Retirement Plan Consultants
|
|
Retirement Relationship Manager MAP Retirement
|
|
Managing Director - Operations, Benefits Daybright Financial
|
|
July Business Services
|
|
Southern Pension Services
|
|
Anchor 3(16) Fiduciary Solutions
|
|
BPAS
|
|
Pentegra
|
|
Regional Vice President, Sales MAP Retirement USA LLC
|
|
ESOP Administration Consultant Blue Ridge Associates
|
Free Newsletters
“BenefitsLink continues to be the most valuable resource we have at the firm.”
-- An attorney subscriber
|
|
| Webinars and Podcasts |
> | Upcoming | On-Demand |
| Conferences | > | Upcoming | Grouped by Location |
| All Webinars, Podcasts and Conferences | > | Upcoming | Grouped by Sponsor |
View More MedCity News Webinars, Podcasts and Conferences
Self-insured Employers Weigh Benefits of GLP-1 DrugsMedCity News |
|
Nov. 20, 2024 On-Demand Podcast |
|
At a time when self-insured employers are searching for ways to address escalating healthcare costs, the rise of GLP-1 drugs for weight loss poses some interesting questions for employers. Could investment in these pricey drugs as a health benefit stem the cost of chronic conditions in the long term? How do employers decide who should get access to these drugs, originally developed for Type 2 diabetes? How can employers be sure employees will develop healthy habits like changing diet and exercise routines so they get a return on their investment? In a conversation with MedCity News Editor-in-Chief Arundhati Parmar, Personify Health Chief Medical Officer Jeff Jacques talks about the different types of GLP-1 drugs, what portion of employers currently offer the medications, and how many employers are considering making them part of their health benefit offering in the future. |